■ LECTURE OVERVIEW: Pompe Disease (Glycogen Storage Disease Type II) is a lysosomal storage disease that impairs the degradation of a small fraction of cellular glycogen, leading to multi-organ tissue destruction.
■ METABOLIC INFRASTRUCTURE:
1. Enzymatic Void: Autosomal recessive deficiency of Lysosomal Acid Alpha-1,4-Glucosidase (also called acid maltase).
2. Compartment Sequestration: Unlike other glycogen storage diseases, the defect is localized within lysosomes, which take up intracellular glycogen via autophagy but are unable to hydrolyze its alpha-1,4 and alpha-1,6 linkages.
3. Intralysosomal Glycogen Aggregation: Glycogen accumulates selectively within lysosomal vacuoles of major metabolically active tissues, primarily cardiac, skeletal, and smooth muscle fibers.
4. Myofibril Displacement: Cellular organelles are displaced, and myofibrillar architecture is completely disrupted by hypertrophying lysosomes, causing early muscle destruction.
■ TOXICOLOGICAL OVERDOSAGE PROTOCOL:
Toxic absorption or cumulative exposure results in receptor saturation, chemical cell damage, or severe secondary target-organ failure. Immediate toxicological profiles dictate serum or urine screens.
■ EPIDEMIOLOGICAL PROFILE & DENSITY CORRELATIONS:
Global burden patterns reveal notable associations with lifestyle habits, regional environmental factors, and inherited traits.
[HY-BOARD-1359]
🌟 Dynamic Clinical Key:
Infantile-onset Pompe disease presents with a classic triad: profound hypotonia (floppy infant), macroglossia, and massive hypertrophic cardiomyopathy resulting in early cardiorespiratory failure. 'Pompe trashes the Pump'—unlike other GSDs, patients have normal blood glucose levels as cytoplasmic glycogenolysis is fully intact. Administer physiological antidotes and active elimination therapies (activated charcoal or hemodialysis) without delay. Focus screening efforts on high-risk geographic regions to maximize clinical yield.